Matthew Campobasso Sells 1,651 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) General Counsel Matthew Campobasso sold 1,651 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total transaction of $13,488.67. Following the transaction, the general counsel now directly owns 54,301 shares of the company’s stock, valued at approximately $443,639.17. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Enfusion Trading Up 0.5 %

Shares of ENFN stock opened at $8.40 on Thursday. The company has a market capitalization of $1.08 billion, a PE ratio of 280.09, a price-to-earnings-growth ratio of 1.94 and a beta of 0.96. The firm has a fifty day simple moving average of $9.10 and a 200-day simple moving average of $9.07. Enfusion, Inc. has a twelve month low of $7.52 and a twelve month high of $11.56.

Enfusion (NYSE:ENFN) last announced its earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.05). The firm had revenue of $48.05 million during the quarter, compared to analysts’ expectations of $47.67 million. Enfusion had a net margin of 1.40% and a return on equity of 6.60%. During the same quarter last year, the company posted $0.04 earnings per share. Equities research analysts predict that Enfusion, Inc. will post 0.09 EPS for the current year.

Wall Street Analyst Weigh In

ENFN has been the subject of several research analyst reports. Morgan Stanley initiated coverage on shares of Enfusion in a research report on Friday, May 10th. They set an “overweight” rating and a $11.00 price target for the company. The Goldman Sachs Group lowered shares of Enfusion from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $9.00 to $8.00 in a research report on Wednesday, February 28th. Finally, Bank of America boosted their price objective on shares of Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a research note on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC boosted its stake in Enfusion by 29.0% during the 3rd quarter. Barclays PLC now owns 10,809 shares of the company’s stock valued at $96,000 after acquiring an additional 2,430 shares during the last quarter. California State Teachers Retirement System boosted its stake in Enfusion by 11.0% during the 1st quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock valued at $333,000 after acquiring an additional 3,556 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Enfusion during the 1st quarter valued at $44,000. Swiss National Bank raised its holdings in shares of Enfusion by 17.4% during the fourth quarter. Swiss National Bank now owns 58,100 shares of the company’s stock worth $564,000 after purchasing an additional 8,600 shares during the period. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Enfusion by 680.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after purchasing an additional 8,627 shares during the period. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.